UroGen Pharma Ltd.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (see signature page hereto)
SIGNATURES AND POWER OF ATTORNEY
We, the undersigned directors and officers of UroGen Pharma Ltd., hereby severally constitute and appoint Elizabeth Barrett and Chris Degnan, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Elizabeth Barrett | President, Chief Executive Officer and Director | March 2, 2026 |
| Elizabeth Barrett | (Principal Executive Officer) | |
| /s/ Chris Degnan | Chief Financial Officer | March 2, 2026 |
| Chris Degnan | (Principal Financial and Accounting Officer) | |
| /s/ Arie Belldegrun | Chair | March 2, 2026 |
| Arie Belldegrun, M.D. | ||
| /s/ Cynthia Butitta | Director | March 2, 2026 |
| Cynthia Butitta | ||
| /s/ Leana S. Wen | Director | March 2, 2026 |
| Leana S. Wen, M.D., M.Sc. | ||
| /s/ Stuart Holden | Director | March 2, 2026 |
| Stuart Holden, M.D. | ||
| /s/ James Robinson Jr. | Director | March 2, 2026 |
| James Robinson Jr. | ||
| /s/ Dan Wildman | Director | March 2, 2026 |
| Dan Wildman | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.